Fluicell introduces BioPen®FLEX
At the request of our customers, Fluicell is thrilled to introduce BioPen®FLEX, a product exclusively developed for experiments using upright microscopes. This product almost doubles the addressable market for the BioPen range. BioPen FLEX features a longer microfluidic tip and a thinner holder than previous models, thus giving better access to cell samples with limited working distance. Researchers can now carry out studies on individual cells and tissues with the highest resolution using another type of commonly used microscope setups.
The BioPen FLEX system has all the benefits of the established BioPen series. The classic BioPen tip and holder, optimized for inverted microscopes, will now be marketed as BioPen® PRIME. The BioPen FLEX and BioPen PRIME systems are interchangeable component platforms, specially designed to meet the requirements for drug testing and cell biology with single cells or thin tissues.
"We are constantly working to improve the BioPen platform in our strategy to provide the market with state-of-the-art technologies that can help researchers get critical data. This case is particularly stimulating as the product was promptly requested by our customers. We are in a strong position to quickly meet our customers' requirements since we have all the knowledge and skills to modify and develop our products with our own R & D and production facility", says Dr. Gavin DM Jeffries, CTO at Fluicell.
More information, please contact:
Victoire Viannay, CEO Fluicell, +46 725 654 205, email@example.com
Fluicell, based in Gothenburg Sweden, is a company that has commercialized a product portfolio to process and study single cells, primarily in the field of drug development. Fluicell sells the research tools Biopen® and Dynaflow® Resolve, which today allow researchers to study, process and measure drug effects in single cells at a unique level of detail. As a further development of the existing product portfolio, Fluicell develops a unique high-tech bioprinting technology in both 2D and 3D, under the name Biopixlar ™ Retina. With this system, complex tissue-like structures can be created where positioning of individual cells can be controlled. More information: www.fluicell.com Mangold Fondkommission AB, +46-8-5030 1550, is the company’s Certified Adviser. The law firm Delphi AB is legal adviser to the company.
This information is of a kind that Fluicell AB (publ) is required to disclose under the EU Market Abuse Regulation. The information was submitted for publication 26 April 2018.